Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will
be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide
treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment,
dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body
weight in patients with T1D and overweight or obesity when compared to insulin treatment
alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented
to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in
range, reduce insulin requirements, and reduce the severity of comorbidities in people with
obesity and T1D. This trial includes a 6 month follow-up period.